We'll see. Even if DCVax-L is approved, UK commercial oncology market is 1/10th of the U.S. and NICE has been very restrictive on high cost personalized oncology treatments. It took 5 years before CAR-T treatments to see government reimbursement and that was just the NICE charity for only about 100 patients a year. Not very big revenue potential if it is actually approved.
Market Data 
Markets 
AI
